Testing a new intravenous medication for nerve pain safety

Plain-English translation of NCT07697560 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage clinical trial testing a new medication called AH-008 to see if it is safe and how the body processes it. Healthy volunteers will receive a single intravenous infusion of the medication at different dose levels. The goal is to gather basic safety information before testing this treatment in patients who have nerve pain caused by cancer chemotherapy.

Nerve pain from cancer chemotherapy can be severe and persistent, and current treatment options are limited. This trial is the first step in developing this medication—researchers need to ensure it is safe and well-tolerated in healthy people before testing it in patients who actually have this type of nerve damage.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have a healthy body weight and BMI between 19 and 32
you are in good overall health with no serious medical conditions
you are female and either cannot have children or are postmenopausal, OR you are male with appropriate reproductive status or using effective contraception
you can commit to the study procedures and provide written consent

You likely don't qualify if…

you have a serious medical condition affecting your heart, nervous system, kidneys, liver, or immune system
you have a history of autoimmune disease or nervous system disorders like Guillain-Barré syndrome
you have severe allergies to medications or foods, or a history of severe allergic reactions
you have HIV, hepatitis B, or hepatitis C
you are pregnant or nursing, or unable to use effective contraception if applicable

What participation looks like

Participants will visit the research clinic to receive a single intravenous infusion of the medication (or placebo) as part of one of four dose groups. The study will involve screening visits to confirm eligibility, the infusion visit, and follow-up visits to monitor how your body responds and processes the medication. The entire study period will involve careful monitoring through blood tests, vital signs, and heart activity checks (ECG).

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(1 site)

United States

ICON Clinial Research Unit, Salt Lake City, Utah